The Bayer-Monsanto Deal Won’t Eat the Cannabis Industry. Yet.

Submitted by Marijuana News on Fri, 09/16/2016 – 08:10

 

The news that Monsanto is being bought by Bayer probably won’t be well received in the cannabis sector. The deal brings together two research powerhouses that, reportedly, have long eyed cannabis as a possible new business. The worry is that the combined firm will have the financial and political influence to do to cannabis what it has already done to corn, tobacco, and other cash crops—namely, use pricy patented cannabis seeds (Roundup Ready Blue Dream, anyone?) that favor large-scale operators and rigidly control how all cannabis farmers farm. The merger, in other words, could be the first step toward Big Cannabis.

In truth, it’s far from certain just how worried “small cannabis” should be. On the one hand, Bayer clearly has designs on the multi-billion-dollar cannabis market. The German firm has been working with GW Pharmaceuticals on a cannabis-based medicinal extract since 2003. And while Monsanto says it “has not and is not working on GMO marijuana,” the company will soon enjoy access to Bayer’s cannabis expertise, which, given Monsanto’s control-through-litigation tactics, might lead one to imagine some pretty bleak scenarios.

That said, it’s hardly clear that this merger makes those scenarios—or Big Cannabis generally—any more plausible.

First, as a practical matter, the merger itself is still just a theory. Monsanto’s shareholders accepted Bayer’s $66 billion buyout offer, but the mega-dealneeds approval from American and German regulators. And given the firms’ massive market share (it would control more than a quarter of the world’s seed and fertilizer business) on top of strong antitrust sentiment worldwide, that approval is hardly assured. And, as a side note, 60 to 80 percent of all mergers fail.

Second, even if approved, a Bayer-Monsanto enterprise likely wouldn’t launch a cannabis product until federal prohibition is lifted. It’s the same reason Big Tobacco hasn’t completely taken over cannabis, despite a decades-old interest in doing so: Massive corporations need massive volume sales, which, in the case of cannabis, is hard to do without a fully open national marketplace. Yes, some in Big Pharma are now reportedly lobbying in favor of legalization—but there’s hardly a sector-wide consensus, as the recent anti-legalization effort by Insys Therapeutics underscores.

Third, even if the feds legalized cannabis tomorrow, a Bayer-Monsanto mega-corporation probably won’t result in any retail cannabis products for some time. It’s true that Bayer has already partnered with pharmaceutical firms that are doing trials of cannabis drugs. Also, Monsanto may be less than candid when it says it hasn’t (yet) tinkered with cannabis’s genetics. But however far along their respective cannabis research efforts are, turning research into commercial product takes years, especially in a market as heavily regulated and politically fragmented as cannabis will continue to be.

Fourth, when it comes to the rise of Big Cannabis, a Bayer-Monsanto merger would merely add to a process that is already well underway. The seed and drug industries are hardly the first mainstream sectors to try to colonize cannabis. Since the start of state legalization, nearly every outside industry with a conceivable cannabis play—tobacco of course, but also food and beverage, clothing, health & wellness, tourism, and Silicon Valley venture capital—has been scrambling to bring the cannabis sector out of the margins and into the mainstream.

More to the point, as the cannabis community itself has matured, it has been moving incrementally toward a business model that, if one didn’t know better, looks surprisingly corporate. For example, with competitive pressures squeezing retail margins, a steady stream of independent retailers have been selling out to larger, more cost-efficient retail chains. This is especially the case in Colorado. Likewise, in a mirror image of the larger faming business, struggling small-scale cannabis farms are being consolidated into larger scale operations whose managers (and investors) are anxiously adopting any method, or technology, that might help them boost output and lower costs. Five or ten years from now, will those farms turn their noses up at a genetically engineered cannabis strain that promises more bang for the buck? More to the point, will their customers?

And therein lies the rub. It may be tempting to see mergers like this one as a threat to the traditional cannabis community, a culture that values a diverse mix of independent small-scale operators. Make no mistake: A merger of this magnitude does promise big changes for global agriculture. But in a cannabis sector that is looking more and more like any other consumer sector, the larger factor may the changing priorities of the cannabis consumer. In the end, the customer’s dollar determines which products—and companies—succeed or fail.

Authored By: 

Leafly

Region: 

United States

Germany

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you’d like to promote your product or service in this area after every article, contact us.

CONTINUE READING…

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s